ELK1 silencing (Fig. 5b) or treatment with the MEK inhibitor Trametinib decreased miR-30c and miR-21 expression levels in two different NSCLC cell lines (Fig. 5c; Supplementary Figure 7i). The gene discussed is ELK1; the disease is non-small cell lung carcinoma.